References
- Kiljander T O, Harding S M, Field S K, Stein M R, Nelson H S, Ekelund J, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173(10)1091–1097
- Partridge A H, Wang P S, Winer E P, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21(4)602–606
- Szefler S J, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008; 372(9643)1065–1072
- Wenzel S, et al. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 2341–2351
- Moore W C, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's severe asthma research program. J Allergy Clin Immunol 2007; 119(2)405–413
- ten Brinke A, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26(5)812–818
- Wenzel S E, et al. IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med 2007; 175(6)570–576
- Sandford A J, et al. Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 2000; 106: 135–140, (1 Pt 1)
- Lee J H, et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007; 132(6)1882–1889
- Miranda C, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113(1)101–108
- Busse W, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108(2)184–190
- Soler M, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18(2)254–261
- Bousquet J, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60(3)302–308
- Wenzel S, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370(9596)1422–1431
- Tantisira K G, et al. Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med 2008; 178(4)325–331
- Evsyukova H V. Aspirin-sensitive asthma due to diffuse neuroendocrine system pathology. Neuro Endocrinol Lett 2002; 23(4)281–285
- Simpson J L, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177(2)148–155
- Wenzel S E, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160(3)1001–1008
- Simpson J L, et al. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Respir Crit Care Med 2005; 172(5)559–565
- Green R H, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360(9347)1715–1721
- Komakula S, et al. Body mass index is associated with reduced exhaled nitric oxide and higher exhaled 8-isoprostanes in asthmatics. Respir Res 2007; 8: 32
- Green R H, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57(10)875–879
- Lazarus S C, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175(8)783–790
- Peters-Golden M, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006; 27(3)495–503